Cancers have been recognized as a major health problem in patients with HIV. The first cases reported, before the existence of the virus was proven, involved patients with immunosuppression and a history of illness characterized by fever, weight loss and/or lymphadenopathy lasting weeks of months. As the population grows older, a consequence of better and largely available treatments, the impact of non-AIDS-defining cancers (NADC) is having a greater impact on the management of HIV infected patients. Studies of different subtypes of HIV-1 in Romania show a very high prevalence of subtype F1, with values between 70% - 90% or the patients being infected with this strain. The study of HIV infected population in Romania is important for identifying particularities of the subtype F1 evolution.
We conducted a prospective study on HIV positive patients under HAART treatment from the Constanta Regional Centre, for a period of eight years, between 2007-2015. All causes of new discovered cancers were recorded with the occasion of subsequent visits that are done on a regular basis. For comparison we used official data from of new diagnosed cancers from reports on health status for Constanta County for the same time period. The adjusted incidence ratio is 955.18/100000patient-years (95% CI 446.58 – 1463.75/100000 patient-years). As observed in similar studies conducted.
HIV patients that undergo HAART treatment have an increased risk of all cancers significantly higher than what is observed in the general population. Considering this, better screening programs have to be developed and implemented for this population. Also, because of the suspicioned high number of HIV infected patients that are not diagnosed, a screening program for HIV should be implemented for all newly diagnosed patients with any type of malignancy.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Centers for Disease C. (1981). Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California. MMWR Morb Mortal Wkly Rep 30(25) 305-308.
2. Haverkos H. W. & Curran J. W. (1982). The current outbreak of Kaposi’s sarcoma and opportunistic infections. CA Cancer J Clin 32(6) 330-339.
3. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program Center for Infectious Diseases. (1987). MMWR Morb Mortal Wkly Rep 36 Suppl 1 1s-15s.
4. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. (1992). MMWR Recomm Rep 41(Rr-17) 1-19.
5. Schneider E. Whitmore S. Glynn K. M. Dominguez K. Mitsch A. & McKenna M. T. (2008). Revised surveillance case definitions for HIV infection among adults adolescents and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States 2008. MMWR Recomm Rep 57(Rr-10) 1-12.
6. Marconi V. C. Grandits G. A. Weintrob A. C. Chun H. Landrum M. L. Ganesan A. . . . Infectious Disease Clinical Research Program H. I. V. W. G. (2010). Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 7 14. doi: 10.1186/1742-6405-7-14
7. Miailhes P. Trabaud M. A. Pradat P. Lebouche B. Chevallier M. Chevallier P. & Trepo C. (2007). Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 45(5) 624-632. doi: 10.1086/520752
8. Lloyd-Smith E. Brodkin E. Wood E. Kerr T. Tyndall M. W. Montaner J. S. & Hogg R. S. (2006). Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 20(3) 445-450. doi: 10.1097/01.aids.0000206508.32030.92
9. Grover S. A. Coupal L. Gilmore N. & Mukherjee J. (2005). Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 95(5) 586-591. doi: 10.1016/j.amjcard.2004.11.004
10. Madeddu G. Fois A. G. Calia G. M. Babudieri S. Soddu V. Becciu F. & Mura M. S. (2013). Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? Infection 41(2) 347-353. doi: 10.1007/s15010-012-0330-x
11. Menezes A. M. Torelly J. Jr. Real L. Bay M. Poeta J. & Sprinz E. (2011). Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS One 6(10) e26042. doi: 10.1371/journal.pone.0026042
12. Chen C. H. Chung C. Y. Wang L. H. Lin C. Lin H. L. & Lin H. C. (2015). Risk of cancer among HIV-infected patients from a population-based nested case-control study: implications for cancer prevention. BMC Cancer 15 133. doi: 10.1186/s12885-015-1099-y
13. D’Souza G. Wiley D. J. Li X. Chmiel J. S. Margolick J. B. Cranston R. D. & Jacobson L. P. (2008). Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 48(4) 491-499. doi: 10.1097/QAI.0b013e31817aebfe
14. Hessol N. A. Pipkin S. Schwarcz S. Cress R. D. Bacchetti P. & Scheer S. (2007). The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 165(10) 1143-1153. doi: 10.1093/aje/kwm017
15. Louie J. K. Hsu L. C. Osmond D. H. Katz M. H. & Schwarcz S. K. (2002). Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy San Francisco 1994-1998. J Infect Dis 186(7) 1023-1027. doi: 10.1086/343862
16. Smith C. J. Ryom L. Weber R. Morlat P. Pradier C. Reiss P. & Lundgren J. D. (2014). Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384(9939) 241-248. doi: 10.1016/s0140-6736(14)60604-8
17. Stanojevic M. Alexiev I. Beshkov D. Gokengin D. Mezei M. Minarovits J. . . . Paraskevis D. (2012). HIV1 molecular epidemiology in the Balkans: a melting pot for high genetic diversity. AIDS Rev 14(1) 28-36.
18. Paraschiv S. Otelea D. Dinu M. Maxim D. & Tinischi M. (2007). Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. Int J Infect Dis 11(2) 123-128. doi: 10.1016/j.ijid.2005.11.006
19. Paraschiv S. Foley B. & Otelea D. (2011). Diversity of HIV-1 subtype C strains isolated in Romania. Infect Genet Evol 11(2) 270-275. doi: 10.1016/j.meegid.2010.07.002
20. Bandea C. I. Ramos A. Pieniazek D. Pascu R. Tanuri A. Schochetman G. & Rayfield M. A. (1995). Epidemiologic and evolutionary relationships between Romanian and Brazilian HIV-subtype F strains. Emerg Infect Dis 1(3) 91-93. doi: 10.3201/eid0103.950305
21. Manolescu L. Temereanca A. Diaconu C. C. & Ruta S. (2011). Correlation between resistance profile and immunosuppression in heavily treated HIV-1 infected Romanian patients. Romanian biotechnological letters 16(4) 6439-6449.
22. Guimaraes M. L. Vicente A. C. Otsuki K. da Silva R. F. Francisco M. da Silva F. G. & Bello G. (2009). Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates. Retrovirology 6 39. doi: 10.1186/1742-4690-6-39
23. Lai A. Ciccozzi M. Franzetti M. Simonetti F. R. Bozzi G. Binda F. . . . Zehender G. (2014). Local and global spatio-temporal dynamics of HIV-1 subtype F1. J Med Virol 86(2) 186-192. doi: 10.1002/jmv.23783
24. Breslow N. E. (1987). Statistical methods in cancer research. Volume II - The design and analysis of cohort studies (Vol. no. 82): International Agency for Research on Cancer.
25. Jensen O. M. Parkin D. M. MacLennan R. Muir C. S. & Skeet R. G. (1991). Cancer Registration: Principles and Methods (Vol. No. 95): International Agency for Research on Cancer.
26. VOLUMUL I: POPULAŢIA STABILĂ (REZIDENTĂ) – STRUCTURA DEMOGRAFICĂ. (2011). 2015 from http://www.recensamantromania.ro/noutati/volumul/